News articles about Catalyst Pharmaceuticals (NASDAQ:CPRX) have been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3670067361327 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Several research firms have weighed in on CPRX. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Zacks Investment Research downgraded Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Piper Jaffray Companies set a $6.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, SunTrust Banks, Inc. set a $5.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 31st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.50.

Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) opened at $3.36 on Friday. Catalyst Pharmaceuticals has a one year low of $1.01 and a one year high of $3.39.

In related news, insider Patrick J. Mcenany bought 20,000 shares of the stock in a transaction dated Tuesday, September 5th. The shares were purchased at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the purchase, the insider now directly owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.60% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Catalyst Pharmaceuticals (CPRX) Earning Somewhat Positive News Coverage, Study Finds” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.